Antonelli A, Ferri C, Fallahi P, Ferrari S M, Giuggioli D, Colaci M, Manfredi A, Frascerra S, Franzoni F, Galetta F, Ferrannini E
Department of Internal Medicine, University of Pisa School of Medicine, Via Roma, 67, I-56100, Pisa, Italy.
Rheumatology (Oxford). 2008 Jan;47(1):45-9. doi: 10.1093/rheumatology/kem313.
To measure serum levels of CXCL10 and CCL2 chemokines in patients with SSc, and relate the findings to clinical phenotype and disease progression.
Serum CXCL10 and CCL2 were assayed in 72 consecutive newly diagnosed SSc patients and in 72 sex- and age-matched controls. In 37 SSc and 37 controls, serum CXCL10 and CCL2 were re-evaluated 5 yrs later.
SSc at onset showed significantly higher CXCL10 serum levels than controls (216 +/- 126 vs 92 +/- 53 pg/ml; P < 0.0001), as well as CCL2 (388 +/- 172 vs 318 +/- 120 pg/ml; P = 0.01). CXCL10 was significantly increased in SSc with interstitial lung involvement or with kidney involvement (P = 0.01 and P = 0.02, respectively). A significant decrease of CXCL10 was observed from the baseline after 5 yrs in SSc (137 +/- 112 vs 270 +/- 122 pg/ml, respectively; P < 0.0001), while no significant change was observed for CCL2 (418 +/- 176 vs 405 +/- 164 pg/ml; P = NS); the CCL2/CXCL10 ratio significantly increased at the fifth year (1.7 +/- 0.8 vs 3.5 +/- 2.5; P < 0.0001). No significant variations were observed in controls from the basal to the 5-yr evaluation with regards to CXCL10, CCL2 or CCL2/CXCL10 ratio.
Our study demonstrates high serum levels of CXCL10 (Th1) and CCL2 (Th2) chemokines in newly diagnosed SSc. High values of CXCL10 are associated with a more severe clinical phenotype (lung and kidney involvement). CXCL10 declined during the follow-up, while CCL2 remained unmodified, suggesting that the disease progresses from the early Th1 inflammatory condition to the advanced Th2-like stage.
测定系统性硬化症（SSc）患者血清中趋化因子CXCL10和CCL2的水平，并将结果与临床表型和疾病进展相关联。
对72例连续新诊断的SSc患者和72例年龄及性别匹配的对照者进行血清CXCL10和CCL2检测。在37例SSc患者和37例对照者中，5年后再次评估血清CXCL10和CCL2水平。
SSc发病时血清CXCL10水平显著高于对照组（216±126对92±53 pg/ml；P<0.0001），CCL2水平亦如此（388±172对318±120 pg/ml；P = 0.01）。在合并间质性肺疾病或肾脏受累的SSc患者中，CXCL10显著升高（分别为P = 0.01和P = 0.02）。5年后，SSc患者CXCL10从基线水平显著下降（分别为137±112对270±122 pg/ml；P<0.0001），而CCL2无显著变化（418±176对405±164 pg/ml；P = 无显著性差异）；第5年时CCL2/CXCL10比值显著升高（1.7±0.8对3.5±2.5；P<0.0001）。在对照组中，从基线到5年评估期间，CXCL10、CCL2或CCL2/CXCL10比值均未观察到显著变化。
我们的研究表明，新诊断的SSc患者血清中CXCL10（Th1型）和CCL2（Th2型）趋化因子水平较高。CXCL10高水平与更严重的临床表型（肺和肾脏受累）相关。随访期间CXCL10下降，而CCL2保持不变，提示疾病从早期Th1炎症状态进展至晚期Th2样阶段。
